WILMINGTON – Prelude Therapeutics, the burgeoning cancer treatment research company, recently named its first president while it furthers research on two lead drugs and preps two additional ones for studies. Dr. Jane Huang, the current ...
WILMINGTON – Cancer treatment research company Prelude Therapeutics has signed a major lease for its future headquarters at the Chestnut Run Innovation and Science Park, the first new tenant at the former DuPont research and ...
WILMINGTON – Cancer research company Prelude Therapeutics recently secured $5.5 million in state taxpayer-backed grants to move to new, larger labs and more than double its workforce in the state. The recent infusion of state ...
WILMINGTON – A few days after announcing that it would offer 1.75 million new shares on the market, startup cancer research company Prelude Therapeutics increased its offering to more than 2.2 million voting shares. The ...
WILMINGTON – The hot biotech startup Prelude Therapeutics announced Jan. 4 that it intends to offer 1.75 million shares of its common stock, according to regulatory filings. The clinical-stage precision oncology company also reported that ...